Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 42.2% from the January 31st total of 96,000 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average daily trading volume, of 64,900 shares, the short-interest ratio is presently 0.9 days.

Hedge Funds Weigh In On Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. Atlas Legacy Advisors LLC purchased a new position in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned about 0.56% of Lixte Biotechnology at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Stock Performance

Shares of NASDAQ:LIXT traded down $0.03 during trading on Tuesday, reaching $1.19. 10,689 shares of the stock traded hands, compared to its average volume of 315,995. The stock has a market cap of $2.67 million, a P/E ratio of -0.68 and a beta of -0.04. The stock has a 50-day moving average of $2.09 and a two-hundred day moving average of $1.95. Lixte Biotechnology has a 52-week low of $1.17 and a 52-week high of $4.40.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.